相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Variation in Catechol-O-Methyltransferase Is Associated with Duloxetine Response in a Clinical Trial for Major Depressive Disorder
Roy H. Perlis et al.
BIOLOGICAL PSYCHIATRY (2009)
Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective
David H. Adams et al.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2008)
Clinical, Functional, and Economic Ramifications of Early Nonresponse to Antipsychotics in the Naturalistic Treatment of Schizophrenia
Haya Ascher-Svanum et al.
SCHIZOPHRENIA BULLETIN (2008)
Predicting antipsychotic drug response - Replication and extension to six weeks in an international olanzapine study
Stefan Leucht et al.
SCHIZOPHRENIA RESEARCH (2008)
Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia
Bruce J. Kinon et al.
SCHIZOPHRENIA RESEARCH (2008)
Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting
Byungsu Kim et al.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2008)
Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research
M. J. Arranz et al.
MOLECULAR PSYCHIATRY (2007)
Catechol-O-methyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence
Wade H. Berrettini et al.
BIOLOGICAL PSYCHIATRY (2007)
DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients
T Lencz et al.
AMERICAN JOURNAL OF PSYCHIATRY (2006)
Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment
JR Bishop et al.
SCHIZOPHRENIA RESEARCH (2005)
Remission in schizophrenia: Proposed criteria and rationale for consensus
NC Andreasen et al.
AMERICAN JOURNAL OF PSYCHIATRY (2005)
The differential clinical and neurocognitive profiles of COMT SNP rs165599 genotypes in schizophrenia
RCK Chan et al.
JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY (2005)
Doparnine D3 receptor Ser9GIy polymorphism and risperidone response
HY Lane et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2005)
Risperidone response and 5-HT6 receptor gene variance:: genetic association analysis with adjustment for nongenetic confounders
HY Lane et al.
SCHIZOPHRENIA RESEARCH (2004)
Neuropsychiatric pharmacogenetics: moving toward a comprehensive understanding of predicting risks and response
JR Bishop et al.
PHARMACOGENOMICS (2004)
Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function
HY Lane et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2004)
Catechol-O-methyltransferase Val108/158Met genotype predicts working memory response to antipsychotic medications
TW Weickert et al.
BIOLOGICAL PSYCHIATRY (2004)
Early prediction of antipsychotic response in schizophrenia
CU Correll et al.
AMERICAN JOURNAL OF PSYCHIATRY (2003)
A haplotype implicated in schizophrenia susceptibility is associated with reduced COMT expression in human brain
NJ Bray et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2003)
Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone
Y Yamanouchi et al.
PHARMACOGENOMICS JOURNAL (2003)
A highly significant association between a COMT haplotype and schizophrenia
S Shifman et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2002)
Association of risperidone treatment response with a polymorphism in the 5-HT2A receptor gene
HY Lane et al.
AMERICAN JOURNAL OF PSYCHIATRY (2002)
Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D2 receptor gene
M Schäfer et al.
AMERICAN JOURNAL OF PSYCHIATRY (2001)
分享论文
